Moreover, in Amaria et al., the CD8+ T-cell tumor infiltrate, PD-L1, and lymphoid markers (granzymes B, CD4/20, PD-1) were higher in the baseline and early-treatment tumor samples of the responders. The gene discussed is CD8A; the disease is neoplasm.